Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2004-04-27 Annual Report
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
OCIS-10KSB DEC 03 AMENMENDMENT NO 1
Annual Report Classification · 100% confidence The document is titled 'FORM 10-KSB/A Amendment No. 1' and is described as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003.' It contains detailed business descriptions, management discussion, and financial information typical of an annual report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of SEC form identifiers and the fiscal year end date further confirm this is an official annual report filing. Therefore, the document should be classified as an Annual Report (10-K).
2004-04-27 English
OCIS 10KSB-DEC 03
Annual Report Classification · 100% confidence The document is titled 'FORM 10-KSB' and is described as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003.' It contains detailed information about the company's business, management, properties, and other disclosures typical of an annual report. The length is substantial (15,000 characters), and it includes comprehensive narrative and financial-related disclosures. There is no indication that this is merely an announcement or a certification. Therefore, this document is classified as an Annual Report (10-K).
2004-04-14 English
OCIS-12B-25-DEC 31, 2003
Regulatory Filings
2004-03-30 English
OCIS-10QSB-SEPTEMBER 30, 2003
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-QSB' and is described as a 'QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended September 30, 2003. It contains detailed unaudited financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. The length of the document is 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of detailed financial data and management discussion confirms it is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2003-11-25 English
OCIS AMENDMENT TO 8-K ON CHANGE OF AUDITORS
Regulatory Filings
2003-11-14 English
OCIS FORM 12B-25-SEPT 30, 2003
Regulatory Filings
2003-11-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.